Since as early as the 1990s, a myriad of AI-driven healthcare technology has successfully reached the market. Perhaps one of most astounding—and maybe slightly unsettling—inventions of all involves the development of Xenobots, a new class of synthetic organisms that blur the lines between the physical, digital and biological worlds.
GFP has given rise to a powerful and versatile molecular toolbox. Cycles of rational design and directed mutagenesis, as well as the isolation of entirely new fluorophores from different species, are continuously pushing the capabilities of fluorescent protein (FP) biosensors to photophysical and biochemical extremes.
The impact of CRISPR-Cas9 technology is undeniable. Yet, it is not without limitations. As such, researchers have since adopted modifications to the original technology as well as alternatives that address some of these limitations.
Free radicals, reactive oxygen species, oxidative stress, oxidation, antioxidants; these terms are used in both scientific and non-scientific contexts, though their meaning and relationships with one another often get confused. These molecules have very important biological roles. First, let’s unravel these terms.
Microcarrier-based biomanufacturing has become well established and now represents a large market across all scales of production. Bioreactors on offer which can use microcarriers range from lab sized, with a few liters of capacity, to factory sized, at hundreds or thousands of liters.
A new wave of innovation is leading to the development of a 2nd generation of ever-more complex organoids, known as assembloids, that will enable more powerful studies to be conducted within the confines of a culture dish allowing greater insights and reducing our reliance on animal models.
